| Pelvic lymph-node staging with 18F-DCFPyL PET/CT prior to extended pelvic lymph-node dissection in primary prostate cancer - the SALT trial - BHE Jansen, YJL Bodar, GJC Zwezerijnen, D Meijer, JP Van Der Voorn, ... European journal of nuclear medicine and molecular imaging 48, 509-520, 2021 | 78 | 2021 |
| External validation and addition of prostate-specific membrane antigen positron emission tomography to the most frequently used nomograms for the prediction of pelvic lymph … D Meijer, PJ van Leeuwen, MJ Roberts, AR Siriwardana, A Morton, ... European urology 80 (2), 234-242, 2021 | 44 | 2021 |
| Detection of prostate cancer with 18F-DCFPyL PET/CT compared to final histopathology of radical prostatectomy specimens: is PSMA-targeted biopsy feasible … YJL Bodar, BHE Jansen, JP Van Der Voorn, GJC Zwezerijnen, D Meijer, ... World journal of urology 39, 2439-2446, 2021 | 34 | 2021 |
| Targeting PSMA revolutionizes the role of nuclear medicine in diagnosis and treatment of prostate cancer WI Luining, MCF Cysouw, D Meijer, NH Hendrikse, R Boellaard, AN Vis, ... Cancers 14 (5), 1169, 2022 | 27 | 2022 |
| Prospective analysis of clinically significant prostate cancer detection with [18F]DCFPyL PET/MRI compared to multiparametric MRI: a comparison with the … YJL Bodar, BGJC Zwezerijnen, PJ van der Voorn, BHE Jansen, RS Smit, ... European journal of nuclear medicine and molecular imaging, 1-12, 2022 | 20 | 2022 |
| The predictive value of preoperative negative prostate specific membrane antigen positron emission tomography imaging for lymph node metastatic prostate cancer D Meijer, HA de Barros, PJ van Leeuwen, YJL Bodar, HG van der Poel, ... The Journal of Urology 205 (6), 1655-1662, 2021 | 16 | 2021 |
| The prognostic value of lymph node staging with prostate‐specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) and extended pelvic lymph … D Meijer, RH Ettema, PJ van Leeuwen, TH van der Kwast, ... BJU international 131 (3), 330-338, 2023 | 13 | 2023 |
| Biochemical persistence of prostate-specific antigen after robot-assisted laparoscopic radical prostatectomy: tumor localizations using PSMA PET/CT imaging D Meijer, ML Donswijk, YJL Bodar, PJ van Leeuwen, HG van der Poel, ... Journal of Nuclear Medicine 62 (7), 961-967, 2021 | 13 | 2021 |
| Prostate-specific membrane antigen positron emission tomography/computed tomography is associated with improved oncological outcome in men treated with salvage radiation … D Meijer, WSC Eppinga, RM Mohede, BGL Vanneste, P Meijnen, ... European urology oncology 5 (2), 146-152, 2022 | 12 | 2022 |
| Reproducibility of PSMA PET/CT imaging for primary staging of treatment-naïve prostate cancer patients depends on the applied radiotracer: a retrospective study MJ Hagens, DE Oprea-Lager, AN Vis, M Wondergem, ML Donswijk, ... Journal of Nuclear Medicine 63 (10), 1531-1536, 2022 | 11 | 2022 |
| Standardised uptake values as determined on prostate‐specific membrane antigen positron emission tomography/computed tomography is associated with oncological outcomes in … YJL Bodar, H Veerman, D Meijer, K de Bie, PJ van Leeuwen, ... BJU international 129 (6), 768-776, 2022 | 10 | 2022 |
| Predicting early outcomes in patients with intermediate‐and high‐risk prostate cancer using prostate‐specific membrane antigen positron emission tomography and magnetic … D Meijer, PJ van Leeuwen, ML Donswijk, TN Boellaard, IG Schoots, ... BJU international 129 (1), 54-62, 2022 | 10 | 2022 |
| Management impact of 18F-DCFPyL PET/CT in hormone-sensitive prostate cancer patients with biochemical recurrence after definitive treatment: a multicenter … D Meijer, PJ van Leeuwen, PMJ Oosterholt, YJL Bodar, HG van der Poel, ... European journal of nuclear medicine and molecular imaging 48, 2960-2969, 2021 | 10 | 2021 |
| Nuclear imaging for bone metastases in prostate cancer: the emergence of modern techniques using novel radiotracers WI Luining, D Meijer, MR Dahele, AN Vis, DE Oprea-Lager Diagnostics 11 (1), 117, 2021 | 10 | 2021 |
| Clinical verification of 18F-DCFPyL PET-detected lesions in patients with biochemically recurrent prostate cancer D Meijer, BHE Jansen, M Wondergem, YJL Bodar, S Srbljin, ... Plos one 15 (10), e0239414, 2020 | 8 | 2020 |
| Prostate cancer development is not affected by statin use in patients with elevated PSA levels D Meijer, RJA van Moorselaar, AN Vis, IV Bijnsdorp Cancers 11 (7), 953, 2019 | 8 | 2019 |
| The oncological characteristics of non‐prostate‐specific membrane antigen (PSMA)‐expressing primary prostate cancer on preoperative PSMA positron emission tomography/computed … H Veerman, M Donswijk, E Bekers, YJL Bodar, D Meijer, ... BJU international 130 (6), 750, 2022 | 7 | 2022 |
| Predictors of clinically significant prostate cancer in biopsy-naïve and prior negative biopsy men with a negative prostate MRI: improving MRI-based screening with a novel risk … LA van Riel, A Jager, D Meijer, AW Postema, RS Smit, AN Vis, ... Therapeutic advances in urology 14, 17562872221088536, 2022 | 7 | 2022 |
| Prostate specific membrane antigen positron emission tomography/computerized tomography in the evaluation of initial response in candidates who underwent salvage radiation … D Meijer, HB Luiting, PJ van Leeuwen, S Remmers, BHE Jansen, ... The Journal of Urology 205 (4), 1100-1109, 2021 | 7 | 2021 |
| Prostate‐specific membrane antigen positron emission tomography in addition to multiparametric magnetic resonance imaging and biopsies to select prostate cancer patients for … B Geboers, D Meijer, W Counter, A Blazevski, J Thompson, P Doan, ... BJU international 133, 14-22, 2024 | 6 | 2024 |
Vis ANVumcVerified email at vumc.nl
